Ladiratuzumab vedotin, an antibody–drug conjugate that targets SLC39A6/LIV-1, is currently undergoing clinical research as a treatment for metastatic and triple-negative breast cancer [104]. Here, SLC39A6 is linked to triple-negative breast carcinoma.